Media

Latest press releases, media assets and global media contacts

All press releases Annual Report 2022 (PDF - 15.7MB)
Data centre employee
Close Video

Scroll to explore

Press releases

Search our corporate press releases by keyword or date. You can also visit our market websites for press releases from our local operating companies.

12 May 2023

GSK presents pivotal data at ESPID confirming effectiveness of its 5-in-1 meningococcal ABCWY vaccine candidate, with demonstrated coverage against a panel of 110 MenB strains

12 May 2023

Statement: Zantac (ranitidine) litigation

03 May 2023

US FDA approves GSK’s Arexvy, the world’s first respiratory syncytial virus (RSV) vaccine for older adults

27 April 2023

GSK’s respiratory syncytial virus older adult vaccine candidate gains positive European Medicines Agency CHMP opinion

Press releases Other markets
Colleagues in conversation

Media Contacts

Are you a professional journalist with an enquiry for our media team?

Get in touch

Media library

Explore our images and videos for use in the media. 

Lab machine

Image

Equipment assembling respiratory medicine

R&D laboratory

Image

R&D laboratory

Colleagues working in a lab

Image

Scientists working in R&D laboratory

Lady working in a fume cupboard

Image

Scientist using syringe behind protective screen

Gsk House Brentford

Image

GSK House

Dame Emma Walmsley

Image

Dame Emma Walmsley

Our media library

Latest news and reports

Emma Walmsley at Q1 2023 wearing a yellow dress with gold belt

2023 First quarter results announcement

Quarterly results
26 April 2023

We announced our first quarter 2023 results on Wednesday, 26 April.

 

 

Two lab workers carrying out tasks

Our response to the situation in Ukraine

Learn more

Alongside the global community, we share deep concern about the tragic events happening in Ukraine. We are taking actions guided by our purpose, and as a company dedicated to health and care for people and patients.

Covid-19 virus

Our response to Covid-19

Learn more

Since the pandemic began, we have sought ways to harness our scientific expertise and technology to make a difference. Together with our partners we are developing COVID-19 therapeutics and vaccines, and now have assets at various stages of development, including two approved for use (in some markets).

Continue to Careers